Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal executive order directing agencies to accelerate review. The evidence shows real potential for...
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is FDA-cleared and available at licensed clinics across the DMV region. Washington DC has...
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single guided dose can produce meaningful, lasting reductions in PTSD symptoms. The evidence is promising, but also...
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, citing three specific concerns: gaps in safety reporting, insufficient evidence that benefits lasted over time, and questions about who was enrolled in the trials. The MDMA...
RFK Jr. psychedelic therapy support has brought real political attention to substances like psilocybin, MDMA, and ibogaine. For seekers already exploring this space, the shift matters. It does not, however, change what responsible engagement looks like at the...
Psychedelic therapy for veterans is one of the most actively researched areas in mental health today. Clinical trials involving MDMA and psilocybin have shown meaningful reductions in PTSD symptoms for people who found little relief through conventional care. This...
